BUZZ-Citius公司因淋巴瘤药物在接受CAR-T疗法前显示出对患者的益处而上涨

路透中文

Mar 04

BUZZ-Citius公司因淋巴瘤药物在接受CAR-T疗法前显示出对患者的益处而上涨

3月4日 - ** 制药商 Citius Oncology CTOR.O 股价上涨 1.89% 至 1.08 美元

** 该公司称，早期数据显示，在CAR-T疗法之前使用其药物Lymphir可能对侵袭性淋巴瘤患者有益

** 高风险弥漫性大B细胞淋巴瘤是一种快速生长的血癌

** 公司称，在 CAR-T 治疗前服用单剂量 Lymphir 后，14 名患者中有 86% 的病情得到改善，其中一半以上的患者病情得到完全缓解

** 公司称，报告的副作用轻微；所有患者都能继续接受 CAR-T 治疗

** Lymphir 于 2024 年获批用于治疗某些患有罕见皮肤血癌的成年患者。

** 2025 年股价下跌约 13%

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2616518475"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616518475\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616518475?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-04 23:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616518475","market":"us","top_or_hot":-1,"title":"BUZZ-Citius公司因淋巴瘤药物在接受CAR-T疗法前显示出对患者的益处而上涨","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Citius公司因淋巴瘤药物在接受CAR-T疗法前显示出对患者的益处而上涨</title></head><body><p><span>3月4日</span><span> - </span>** 制药商 <a href=\"https://laohu8.com/S/CTOR\">Citius Oncology</a> <span>CTOR.O</span> 股价上涨 1.89% 至 1.08 美元 </p><p>** 该公司称，早期数据显示，在CAR-T疗法之前<span>使用 </span>其药物Lymphir可能对侵袭性淋巴瘤患者<span>有益 </span></p><p>** 高风险弥漫性大B细胞淋巴瘤是一种快速生长的血癌</p><p>** 公司称，在 CAR-T 治疗前<span>服用 </span>单剂量 Lymphir 后，14 名患者中有 86% 的病情得到<span>改善</span>，其中一半以上的患者病情得到完全缓解</p><p>** 公司称，报告<span>的 </span>副作用轻微；所有患者都<span>能 </span>继续接受 CAR-T 治疗</p><p>** Lymphir 于 2024 年获批用于治疗某些患有罕见皮肤血癌的成年患者。</p><p>** 2025 年股价下跌约 13%</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Citius公司因淋巴瘤药物在接受CAR-T疗法前显示出对患者的益处而上涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Citius公司因淋巴瘤药物在接受CAR-T疗法前显示出对患者的益处而上涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-03-04 23:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Citius公司因淋巴瘤药物在接受CAR-T疗法前显示出对患者的益处而上涨</title></head><body><p><span>3月4日</span><span> - </span>** 制药商 <a href=\"https://laohu8.com/S/CTOR\">Citius Oncology</a> <span>CTOR.O</span> 股价上涨 1.89% 至 1.08 美元 </p><p>** 该公司称，早期数据显示，在CAR-T疗法之前<span>使用 </span>其药物Lymphir可能对侵袭性淋巴瘤患者<span>有益 </span></p><p>** 高风险弥漫性大B细胞淋巴瘤是一种快速生长的血癌</p><p>** 公司称，在 CAR-T 治疗前<span>服用 </span>单剂量 Lymphir 后，14 名患者中有 86% 的病情得到<span>改善</span>，其中一半以上的患者病情得到完全缓解</p><p>** 公司称，报告<span>的 </span>副作用轻微；所有患者都<span>能 </span>继续接受 CAR-T 治疗</p><p>** Lymphir 于 2024 年获批用于治疗某些患有罕见皮肤血癌的成年患者。</p><p>** 2025 年股价下跌约 13%</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTXR","symbol_name":"Citius Pharmaceuticals, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nL4S3ZS1GU:1","article_id":"2616518475","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616518475","pubTimestamp":1772636914,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"** 2025 年股价下跌约 13%(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"CTXR":"Citius Pharmaceuticals, Inc.","CTOR":"CITIUS ONCOLOGY INC","BK4139":"生物科技","BK4007":"制药"},"translate_title":"BUZZ-Citius rises as lymphoma drug shows patient benefit before receiving CAR-T therapy","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTXR":0.9,"CTOR":0.9},"content_text":"BUZZ-Citius公司因淋巴瘤药物在接受CAR-T疗法前显示出对患者的益处而上涨3月4日 - ** 制药商 Citius Oncology CTOR.O 股价上涨 1.89% 至 1.08 美元 ** 该公司称，早期数据显示，在CAR-T疗法之前使用 其药物Lymphir可能对侵袭性淋巴瘤患者有益 ** 高风险弥漫性大B细胞淋巴瘤是一种快速生长的血癌** 公司称，在 CAR-T 治疗前服用 单剂量 Lymphir 后，14 名患者中有 86% 的病情得到改善，其中一半以上的患者病情得到完全缓解** 公司称，报告的 副作用轻微；所有患者都能 继续接受 CAR-T 治疗** Lymphir 于 2024 年获批用于治疗某些患有罕见皮肤血癌的成年患者。** 2025 年股价下跌约 13%(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}